摘要
目的评估膳食补充剂Licofor治疗睑板腺功能障碍(MGD)相关干眼的临床效果。方法本研究为随机对照临床试验。纳入2018年12月至2019年10月于中南大学湘雅医院眼科中心眼表专科确诊为MGD相关干眼患者60例120眼,男25例,女35例,年龄(42±13)岁。患者随机分为试验组(30例60眼)和对照组(30例60眼)。两组均采用眼部热敷、抗生素眼膏涂睑缘及人工泪液点眼;试验组联合口服Licofor,对照组联合口服安慰剂。比较治疗前和治疗后4、8、12周两组患者的干眼症状与体征、睑板腺结构与功能、眼睑局部炎症反应。结果试验组和对照组患者在治疗后12周眼表疾病指数(OSDI)评分、泪膜破裂时间(TBUT)、角膜荧光素染色(CFS)、睑缘和睑板腺开口形态、睑板腺排出能力、睑酯性状和睑板腺腺泡周围炎症细胞密度均较治疗前好转,差异均有统计学意义(均P<0.05);且试验组在OSDI评分[16.7(12.5,20.8)比20.8(18.8,22.9)分,P<0.001]、睑缘和睑板腺开口形态、腺泡周围炎症细胞密度[443(318,513)比553(415,676)个/mm^(2),P=0.002]方面较对照组改善均更为明显(均P<0.05)。结论Licofor与常规治疗方法联合应用能更加有效地改善MGD相关干眼患者的干眼症状、睑缘和睑板腺开口形态、睑酯性状、眼睑局部炎症反应。
Objective To evaluate the clinical efficacy of dietary supplement Licofor in the treatment of dry eye associated with meibomian gland dysfunction(MGD).Methods This was a prospective,randomized controlled clinical trial.Sixty patients[25 males,35 females,aged(42±13)years]who had dry eye associated with MGD were recruited in Xiangya Hospital of Central South University from December 2018 to October 2019.The patients were equally divided into two groups:30 cases(60 eyes)in the experimental group and 30 cases(60 eyes)in the control group.All subjects were treated with eye hot compress,artificial tears and antibiotic ointment.After that,the experimental group and control group were received dietary supplementary Licofor or placebo daily for 12 weeks.The symptoms and signs of dry eye,morphology and function of meibomian gland,and inflammatory response were assessed at the beginning,4^(th),8^(th) and 12^(th) week of treatment.Results After 12 weeks of treatment,statistically significant improvements in ocular surface disease index(OSDI)scores,tear break-up time(TBUT),corneal fluorescein staining(CFS),the morphology of eyelid margin,meibomian gland orifice,meibomian gland expressibility,meibum quality,and periglandular inflammatory cell density were determined in both groups(all P<0.05).In the Licofor group,the improvement of OSDI scores[16.7(12.5,20.8)vs 20.8(18.8,22.9),P<0.001],the morphology of eyelid margin,meibomian gland orifice and periglandular inflammatory cell density[443(318,513)vs 553(415,676)/mm^(2),P=0.002]were more significant(all P<0.05).Conclusion The combined treatment of licofor and conventional treatment can significantly improve symptoms of dry eye,the morphology of eyelid margin,meibomian gland orifice,meibum quality,and eyelid inflammation response of dry eye associated with MGD.
作者
彭霞
李雅嘉
陈佑祺
廖敏
刘康成
袁若兰
曹子秦
唐湘波
徐懿
梁敬文
李强翔
王华
Peng Xia;Li Yajia;Yau Kei Chan;Liao Min;Liu Kangcheng;Yuan Ruolan;Cao Ziqin;Tang Xiangbo;Xu Yi;Liang Jingwen;Li Qiangxiang;Wang Hua(Eye Center of Xiangya Hospital,Central South University,Hunan Key Laboratory of Ophthalmology,Changsha 410008,China;Department of Dermatology,Xiangya Hospital,Central South University,Changsha 410008,China;Department of Ophthalmology,Li Ka Shing Faculty of Medicine,the University of Hong Kong,Hong Kong 999077,China;Department of Spine Surgery,Xiangya Hospital,Central South University,Changsha 410008,China;Ningxia Geriatric Disease Clinical Research Center,People′s Hospital of Ningxia Hui Autonomous Region,Yinchuan 750001,China;Department of Ophthalmology,Xiangya Changde Hospital,Changde 415000,China)
出处
《中华医学杂志》
CAS
CSCD
北大核心
2021年第32期2508-2513,共6页
National Medical Journal of China
基金
湖南省自然科学基金(2019JJ40502)
湖南省中医药管理局科技计划项目(201856)
中央引导地方科技发展专项(2020YDDF0043)。
关键词
干眼综合征
睑板腺功能障碍
膳食补充剂
疗效
Dry eye syndromes
Meibomian gland dysfunction
Dietary supplement
Efficacy
